ANGLE plc Clinches Deal with Recursion Pharmaceuticals

ANGLE plc (GB:AGL) has released an update.

ANGLE plc, a trailblazer in liquid biopsy technology, has announced a new collaboration with Recursion Pharmaceuticals to conduct a pilot study using ANGLE’s Parsortix CTC analysis system. This partnership represents ANGLE’s fourth major contract in 2024, cementing its growth in the large pharma services sector. The study’s success could lead to larger contracts, underscoring the potential impact of ANGLE’s innovative solutions in clinical oncology and drug development.

For further insights into GB:AGL stock, check out TipRanks’ Stock Analysis page.